share_log

Should You Think About Buying Dolby Laboratories, Inc. (NYSE:DLB) Now?

Should You Think About Buying Dolby Laboratories, Inc. (NYSE:DLB) Now?

你現在應該考慮收購杜比實驗室公司(紐約證券交易所代碼:DLB)嗎?
Simply Wall St ·  01/03 10:27

Dolby Laboratories, Inc. (NYSE:DLB), is not the largest company out there, but it saw significant share price movement during recent months on the NYSE, rising to highs of US$89.38 and falling to the lows of US$78.28. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether Dolby Laboratories' current trading price of US$85.72 reflective of the actual value of the mid-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let's take a look at Dolby Laboratories's outlook and value based on the most recent financial data to see if there are any catalysts for a price change.

杜比實驗室公司(紐約證券交易所代碼:DLB)並不是目前最大的公司,但近幾個月來,它在紐約證券交易所的股價出現了重大波動,升至89.38美元的高位,跌至78.28美元的低點。一些股價走勢可以爲投資者提供更好的入股機會,並有可能以較低的價格買入。需要回答的問題是,杜比實驗室目前的85.72美元交易價格是否反映了中型股的實際價值?還是它目前被低估了,爲我們提供了買入的機會?讓我們根據最新的財務數據來看看杜比實驗室的前景和價值,看看是否有任何價格變動的催化劑。

Check out our latest analysis for Dolby Laboratories

查看我們對杜比實驗室的最新分析

What Is Dolby Laboratories Worth?

杜比實驗室值多少錢?

According to our price multiple model, which makes a comparison between the company's price-to-earnings ratio and the industry average, the stock price seems to be justfied. We've used the price-to-earnings ratio in this instance because there's not enough visibility to forecast its cash flows. The stock's ratio of 40.61x is currently trading slightly below its industry peers' ratio of 47.35x, which means if you buy Dolby Laboratories today, you'd be paying a reasonable price for it. And if you believe Dolby Laboratories should be trading in this range, then there isn't much room for the share price to grow beyond the levels of other industry peers over the long-term. In addition to this, it seems like Dolby Laboratories's share price is quite stable, which could mean there may be less chances to buy low in the future now that it's trading around the price multiples of other industry peers. This is because the stock is less volatile than the wider market given its low beta.

根據我們的價格倍數模型,該模型將公司的市盈率與行業平均水平進行了比較,股價似乎是合理的。我們在這個例子中使用市盈率是因爲沒有足夠的可見性來預測其現金流。該股票的比率爲40.61倍,目前的交易價格略低於其行業同行47.35倍的比率,這意味着如果您今天收購杜比實驗室,您將爲此支付合理的價格。而且,如果你認爲杜比實驗室應該在這個區間內交易,那麼從長遠來看,股價的增長空間不大超過其他行業同行的水平。除此之外,杜比實驗室的股價似乎相當穩定,這可能意味着既然它的交易價格與其他行業同行的價格倍數接近,未來低價買入的可能性可能就會減少。這是因爲鑑於其低貝塔值,該股票的波動性小於整個市場。

What kind of growth will Dolby Laboratories generate?

杜比實驗室將帶來什麼樣的增長?

earnings-and-revenue-growth
NYSE:DLB Earnings and Revenue Growth January 3rd 2024
紐約證券交易所:DLB收益和收入增長 2024年1月3日

Future outlook is an important aspect when you're looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Although value investors would argue that it's the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. Dolby Laboratories' earnings over the next few years are expected to increase by 57%, indicating a highly optimistic future ahead. This should lead to more robust cash flows, feeding into a higher share value.

當你考慮買入股票時,未來前景是一個重要的方面,特別是如果你是尋求投資組合增長的投資者。儘管價值投資者會爭辯說,最重要的是相對於價格的內在價值,但更有說服力的投資論點是以低廉的價格獲得高增長潛力。杜比實驗室未來幾年的收益預計將增長57%,這表明未來的前景非常樂觀。這應該會帶來更強勁的現金流,從而提高股票價值。

What This Means For You

這對你意味着什麼

Are you a shareholder? DLB's optimistic future growth appears to have been factored into the current share price, with shares trading around industry price multiples. However, there are also other important factors which we haven't considered today, such as the track record of its management team. Have these factors changed since the last time you looked at DLB? Will you have enough confidence to invest in the company should the price drop below the industry PE ratio?

你是股東嗎?DLB樂觀的未來增長似乎已被納入當前股價的因素,股票的交易價格約爲行業價格倍數。但是,我們今天還沒有考慮其他重要因素,例如其管理團隊的往績。自從你上次看DLB以來,這些因素髮生了變化嗎?如果價格跌至行業市盈率以下,您是否有足夠的信心投資該公司?

Are you a potential investor? If you've been keeping an eye on DLB, now may not be the most optimal time to buy, given it is trading around industry price multiples. However, the positive outlook is encouraging for DLB, which means it's worth further examining other factors such as the strength of its balance sheet, in order to take advantage of the next price drop.

你是潛在的投資者嗎?如果您一直在關注DLB,那麼鑑於DLB的交易價格約爲行業倍數,現在可能不是最佳的購買時機。但是,DLB的樂觀前景令人鼓舞,這意味着值得進一步研究其他因素,例如資產負債表的強度,以利用下一次價格下跌的機會。

Diving deeper into the forecasts for Dolby Laboratories mentioned earlier will help you understand how analysts view the stock going forward. At Simply Wall St, we have the analysts estimates which you can view by clicking here.

深入研究前面提到的對杜比實驗室的預測將幫助您了解分析師如何看待該股的未來。在Simply Wall St,我們有分析師的估計,你可以點擊這裏查看。

If you are no longer interested in Dolby Laboratories, you can use our free platform to see our list of over 50 other stocks with a high growth potential.

如果您不再對杜比實驗室感興趣,您可以使用我們的免費平台查看我們列出的其他50多隻具有高增長潛力的股票清單。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St 的這篇文章本質上是籠統的。我們僅使用公正的方法提供基於歷史數據和分析師預測的評論,我們的文章並非旨在提供財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不會考慮最新的價格敏感型公司公告或定性材料。華爾街只是沒有持有上述任何股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論